- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
As an SMN2 splicing modifier, special attention should be paid to hepatotoxicity, rash risk, and drug interactions when using Evrysdi tablets. ...
Evrysdi (Risperidone tablets) is an SMN2 splicing modifier used for the treatment of spinal muscular atrophy (SMA). This drug improves the pati...
The contraindications for Pacritinib mainly include patients with severe heart block and active bleeding, and strict adherence to contraindicat...
Pacritinib is a JAK2/IRAK1 inhibitor used to treat myelofibrosis with severe thrombocytopenia, and strict adherence to dosage regimens and moni...
Pacritinib is a new targeted drug for the treatment of bone marrow fibrosis with severe thrombocytopenia, and its management of side effects su...
Parkitinib may cause side effects such as diarrhea, nausea, and fatigue, which need to be alleviated through dietary adjustments, medication ...
Adagrasib is an oral inhibitor targeting KRASG12C mutations, suitable for second-line treatment of locally advanced or metastatic non-small cel...
Adagrasib is a KRASG12C inhibitor used to treat non-small cell lung cancer carrying KRASG12C mutations. 1. Usage and dosage (1) Standard ...
Adagrasib has clear contraindications for patients with severe liver injury and QTc prolongation, and strict risk assessment and monitoring of ...
As a KRASG12C inhibitor, common side effects such as nausea, vomiting, and fatigue of Adagrasib can be effectively managed through medication a...
